Radiation therapy provides a means to kill large numbers of cancer cells in a controlled location resulting in the release of tumor-specific antigens and endogenous adjuvants. However, by activating pathways involved in apoptotic cell recognition and phagocytosis,...
Cancer patients undergoing cranial irradiation are at risk of developing neurocognitive impairments. Recent evidence suggests that radiation-induced injury to the hippocampi could play an important role in this cognitive decline. As a tool for studying the mechanisms...
The Annual Meeting of the American Society for Radiation Oncology (ASTRO) conference in Boston, September 26 – 28, will see Xstrahl Ltd (Booth 7057) showcase a range of new and updated products and systems. The Medical side of the business will be presenting the updated Photoelectric Therapy system, whilst Xstrahl Life Sciences highlights the recent developments and new accessories for SARRP. The ASTRO Annual Meeting is the world’s most important meeting for the radiation oncology community, with more than 11,000 people attending.
The risk of recurrence following radiation therapy remains high for a significant number of prostate cancer patients. The development of in vitro isogenic models of radioresistance through exposure to fractionated radiation is an increasingly used approach to...
NICE (National Institute for Health and Care Excellence) has announced a new Medtech Innovation Briefing (MIB)1 stating that NHS doctors and commissioners may consider Single Dose Intraoperative Radiotherapy (SD-IORT) using Xstrahl distributed Xoft Axxent eBx as a treatment option for early stage breast cancer patients. A single dose of intraoperative radiotherapy (IORT) is an effective and convenient alternative to daily conventional radiotherapy for appropriate early stage breast cancer patients.
PURPOSE: Non-melanotic skin cancers remain the most commonly diagnosed cancers. Radiotherapy and surgery are the most common treatment options. Radiotherapy has a recurrence rate of up to 20% for basal or squamous cell cancers. One of the difficulties is to determine...
OBJECTIVE: Neuroblastoma has one of the lowest survival rates of all childhood cancers, despite the use of intensive treatment regimens. Preclinical models of neuroblastoma are essential for testing new multimodality protocols, including those that involve...
Over 60% of cancer patients worldwide will receive radiotherapy as a part of their overall treatment plan. Recently, stereotactic body radiation therapy (SBRT) has been recognized as a favorable treatment option for those cancer types that remain inoperable. SBRT administers very high doses of radiation in a small number of fractions, and has been shown to achieve 3-year control rates of roughly 90% in stage 1 NSCLC’s.
Background The radiopharmaceutical 131I-meta-iodobenzylguanidine (131I-MIBG) is an effective treatment for neuroblastoma. However, maximal therapeutic benefit from 131I-MIBG is likely to be obtained by its combination with chemotherapy. We previously reported enhanced...
Contact Us